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Normal pregnancy is an immunotolerant state. Many factors, including environmental,
socioeconomic, genetic, and immunologic changes by infection and/or other causes
of inflammation, may contribute to inter-individual differences resulting in a normal or
pathologic pregnancy. In particular, imbalances in the immune system can cause many
pregnancy-related diseases, such as infertility, abortions, pre-eclampsia, and preterm
labor, which result in maternal/fetal death, prematurity, or small-for-gestational age
newborns. New findings imply that myeloid regulatory cells and regulatory T cells (Tregs)
may mediate immunotolerance during normal pregnancy. Effector T cells (Teffs) have,
in contrast, been implicated to cause adverse pregnancy outcomes. Furthermore, feto-
maternal tolerance affects the developing fetus. It has been shown that the Treg/Teff
balance affects litter size and adoptive transfer of pregnancy-induced Tregs can prevent
fetal rejection in the mouse. Heme oxygenase-1 (HO-1) has a protective role in many con-
ditions through its anti-inflammatory, anti-apoptotic, antioxidative, and anti-proliferative
actions. HO-1 is highly expressed in the placenta and plays a role in angiogenesis and
placental vascular development and in regulating vascular tone in pregnancy. In addition,
HO-1 is a major regulator of immune homeostasis by mediating crosstalk between
innate and adaptive immune systems. Moreover, HO-1 can inhibit inflammation-induced
phenotypic maturation of immune effector cells and pro-inflammatory cytokine secretion
and promote anti-inflammatory cytokine production. HO-1 may also be associated with
T-cell activation and can limit immune-based tissue injury by promoting Treg suppression
of effector responses. Thus, HO-1 and its byproducts may protect against pregnancy
complications by its immunomodulatory effects, and the regulation of HO-1 or its
downstream effects has the potential to prevent or treat pregnancy complications and
prematurity.
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Introduction
There are many physiological adaptations that are essential for a healthy pregnancy. Profound
immunological changes must take place such as dynamic alterations in the proportions of immune
cells in the maternal blood and decidua and of highly specific decidual immune cell types that arise
only during pregnancy. These changes allow for the host to become “non-reactive” to the allogeneic
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fetus and for the establishment of an immunotolerant environ-
ment for this “allogeneic graft” so that a successful implantation
can occur and a healthy, but permissive, feto-placental barrier is
maintained. This complex adaptive process can be disrupted by
maternal and fetal inflammation or infections. It has been shown
that both epigenetic (environmental factors such as pollutants,
nutrition, stress; Murphy, 2007; Shachar et al., 2013; Patel et al.,
2014) and genetic factors (Kaartokallio et al., 2014) cannot only
affect an ongoing pregnancy and subsequent outcomes and result
in phenotypic alterations in the offspring; but also, can result in
germ-line alterations that lead to adverse transgenerational effects
(Skinner, 2014). Heme oxygenase (HO), a ubiquitous and genet-
ically polymorphic enzyme, has three isozymes—the inducible
HO-1, the constitutive HO-2, and HO-3, which appears to be a
pseudogene (McCoubrey et al., 1997). HO is the rate-limiting step
in the heme catabolic pathway, producing equimolar amounts of
iron, carbon monoxide (CO), and biliverdin that is then reduced
to bilirubin. HO-1 has protective effects in many disease states
through its anti-inflammatory, anti-apoptotic, antioxidative, and
anti-proliferative actions (Woo et al., 1998; Zenclussen et al.,
2005). Because it also has immunosuppressive properties, HO-
1 may also have a role in maintaining the immune balance in a
normal pregnancy, as discussed below, is supported by the obser-
vations that suboptimal expression of HO-1 has been shown to be
associated with pregnancy, fetal, and neonatal complications.
Immune System and Immunotolerance
in Normal and Pathologic Pregnancies
A normal pregnancy can be regarded as a series of mechanisms
regulating immunotolerance, starting as early as ovulation and
occurring primarily at the feto-placental junction. Based largely
on murine studies, this traditionally has been attributed to a
T helper 2 (Th2)-skewed immunity in which the production of
IL-4, IL-5, and IL-13 by CD4T cells is prominent. However, recent
studies have shown that this process is much more complex, and
that Th2 responsesmay not play a central role in feto-maternal tol-
erance in humans (Saito et al., 2010; Dimova et al., 2011; Liu et al.,
2011; Schlossberger et al., 2013; Zhao et al., 2015). The immune
cell phenotypes at the feto-placental junction are considerably
different than their peripheral (circulating) counterparts (Saito
et al., 2010; Arck and Hecher, 2013). In the establishment and
maintenance of an immunotolerant feto-placental environment,
the changing phenotypes of key immune cells may be essential.
Many immune cell types undergo changes in phenotypes and
proportions during normal pregnancy and at the time of parturi-
tion. This immunotolerant state is perturbed during pathological
pregnancies.
Contributors to Immunotolerance During Normal
Pregnancy
Decidua/Placenta
Early in human pregnancies, a tolerogenic phenotype predom-
inates in the decidua during implantation of the fetus, which
because of its expression of major and minor histocompatibility
antigens differing from that of the mother, can be considered
an allograft. Uterine natural killer (uNK) cells (Zhao et al.,
2011; Le Bouteiller, 2013) andM2 (alternative) macrophages help
with the initial steps of this process by mediating uterine spiral
artery remodeling, trophoblastic invasion, and immunomodula-
tion (Nagamatsu and Schust, 2010b; Houser, 2012). For exam-
ple, unlike circulating monocyte-derived macrophages after the
uptake of apoptotic trophoblasts, placental M2 macrophages do
not produce inflammatory mediators (Ben Amara et al., 2013),
and hence may limit immune responses and promote immuno-
tolerance. However, as parturition nears, placental macrophages
become predominately an inflammatory (M1) type (Nagamatsu
and Schust, 2010a), contributing to the “physiologic inflamma-
tion” associated with the initiation of parturition. Decidual stro-
mal cells (DSCs) may also contribute to supporting a healthy
feto-placental environment during the first trimester in healthy
human pregnancies. For example, when human decidua cells of
the first trimester of pregnancy were co-cultured with healthy
unrelated donor lymphocytes, DSCswere found to inhibit NK-cell
function, dendritic cell (DC) differentiation, and T-cell responses
(Croxatto et al., 2014). In addition, high numbers of regula-
tory T cells (Tregs) at the feto-maternal interface present from
early to mid-gestation (Guerin et al., 2009) have been shown to
be associated with successful implantation in humans (Guerin
et al., 2009) as well as in mice (Zenclussen et al., 2007). As
pregnancy advances, uNK cells and Tregs decrease in the human
and mouse deciduae. These changes are accompanied by changes
in the composition of the Treg pool. For example, in preg-
nant mice, there is a predominance of thymic-derived (natural)
nTregs that rapidly decrease and an increase of peripherally-
induced Tregs (iTregs) in the blood and uterine lymph nodes
by the conversion of peripheral naïve T cells to iTregs (Teles
et al., 2013). In addition, the two classical Treg cell populations
(CD4+CD25++FoxP3+ andCD4+CD25+FoxP3+) and putative
naïve Tregs (CD4+CD25 FoxP3+) increase significantly in the
decidua of healthy pregnant women (Dimova et al., 2011). These
T-cell changes help sustain a healthy allograft/host environment.
Peripheral Blood
Although the total number of circulating Tregs are not differ-
ent between pregnant and non-pregnant women (Dimova et al.,
2011), the composition of this pool changes dynamically through-
out pregnancy (Zhao et al., 2007). For example, in pregnant
women, the fraction of circulating Tregs that express relatively
high levels of human leukocyte antigen (HLA)-DR is increased
compared to non-pregnant women, and these Tregs are highly
effective at suppressing effector T cells (Teffs; Schober et al.,
2012). During parturition, especially if premature, the suppressive
activity of peripheral blood Tregs decreases (Schober et al., 2012).
Granulocytic myeloid-derived suppressor cells (MDSCs), which,
like Tregs, can inhibit Teffs, increase in the peripheral blood of
healthy pregnant women throughout all trimesters; whereas, the
numbers of monocytic MDSCs remain unchanged (Kostlin et al.,
2014). Conventional CD11c+ DCs, which play an essential role in
inducing the response of antigenically naïve T cells and B cells to
antigens, are present in the circulation in high numbers during
the first trimester compared to healthy non-pregnant women,
and decrease as pregnancy progresses with the lowest absolute
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numbers by the third trimester (Della Bella et al., 2011). The cir-
culating CD11c+ DCs of the third trimester display a phenotype
that suggests incomplete maturation, with relatively high levels of
CD80, CD86, CD40, and CD83, but not HLA-DR; whereas, this
cell type in non-pregnant women displays high levels of all of these
proteins. The reduced expression of HLA-DR is associated with a
decreased capacity of this CD11c+ DC population to allogene-
ically stimulate T cells, suggesting that this phenotypic alteration
might be relevant to limitingmaternal responses to the fetus (Della
Bella et al., 2011). Given these observations, it is plausible that
a combination of alterations in the phenotype and function of
immune cells in the maternal circulation in combination with the
selective trafficking of these cells to the decidua (Arck andHecher,
2013) and to the feto-placental unit (Shechter et al., 2013; Jeanty
et al., 2014)may play an important role in sustaining a healthy fetal
allograft/maternal host relationship.
Impact of Immunotolerance on the Fetus
and Neonate
There is growing evidence that both the maternal and fetal
immune systems contribute to a healthy allograft/host relation-
ship by reciprocal immune alterations via feto-placental immune
trafficking. This in turn affects the health of the developing
fetus and the neonate. Mold et al. (2008) have elegantly shown
that maternal hematopoietic cells are found in the fetus as part
of normal pregnancy and contribute to the generation of fetal
suppressive Tregs that limit responses to non-inherited maternal
HLA haplotypes in utero. Although the immune system of the
developing fetus has been largely inaccessible for study, studies on
cord blood have provided some insights into this relationship.
Granulocytic MDSCs predominate in cord blood at birth
(Rieber et al., 2013). MDSCs are crucial in expanding the Treg
populations in a cell contact- and indoleamine 2,3-dioxygenase
(IDO)-dependent manner (Zoso et al., 2014) in human cord
blood. In fact, in humans and mice, IDO is expressed by tolero-
genic DCs and results in the peripheral conversion of naïve CD4
T cells into Tregs. Despite the predominance of these highly
suppressive cell types in cord blood, neonatesmay not be as highly
immunosuppressed at birth as previously thought. For example,
human fetal DCs isolated from lymph nodes can properly respond
to in vitro stimuli, which supports this hypothesis (Mold et al.,
2008). Therefore, active suppression by regulatory populations of
potential neonatal effector cells may be utmost importance for a
healthy pregnancy outcome.
Impact of Immune Perturbations on Pregnancy
Outcomes
Perturbations in the abovementioned innate and adaptive
immune system components that occur in early and late gestation
have been documented to cause pathologic pregnancy outcomes,
such as fertility problems, defective placentation through
abnormal spiral artery remodeling, miscarriages, abortions, fetal
deaths, preterm labor, pre-eclampsia, and intrauterine growth
restriction (IUGR). HO-1 is believed to be amajor regulator of the
innate and adaptive immune systems, and may be involved in the
interaction between the two systems during pregnancy (Soares
et al., 2009; Koliaraki and Kollias, 2011). Many pregnancy, fetal,
and neonatal complications can be attributed to perturbations
in the maternal and fetal/neonatal immune systems, and a
deficiency in HO-1 may be one such predisposition that disturbs
allograft/host immune homeostasis.
Effect of HO-1 Deficiency on Pregnancy
Outcomes
Impact of Variability in HO-1 Expression
The expression of HO-1 is genetically variable in humans due
to either polymorphisms in the number of (GT)n dinucleotide
repeats in the HO-1 promoter region (with longer repeats being
associated with a decrease in HO-1 gene expression) or HO-1
mutant alleles. Moreover, a relative deficiency in HO-1 has been
linked to a number of pregnancy complications. In both humans
and mice, it can cause a chronic inflammatory state with an
increased susceptibility to oxidative injury; whereas, the complete
absence of HO-1 is lethal. However, there are also conflicting
reports on the role of HO-1 polymorphisms in pregnancy com-
plications. Denschlag et al. (2004) have shown that idiopathic
recurrent miscarriages are associated with shorter (GT)n dinu-
cleotide repeat lengths (27); while longer repeat lengths (>25)
have been reported to be linked to late onset and less severe forms
of pre-eclampsia (Kaartokallio et al., 2014).
In our laboratory, we have observed that HO-1 is highly
expressed in the placenta, and appears to play a role in angiogene-
sis, placental vascular development, and the regulation of vascular
tone during pregnancy (Zhao et al., 2009; Wong et al., 2012). In
addition, a maternal deficiency in HO-1 in mice was found to
affect fetal growth andmaternal-fetal hemodynamics during early
to mid-gestation due to changes in placental angiogenesis and
differentiation of uNK cells (Zhao et al., 2008, 2009, 2011; Wong
et al., 2012). Others have also reported that a deficiency in HO-1
is associated with decreased uNK cells at fetal implantation sites
and results in defective spiral artery remodeling along with aber-
rant expression of vascular factors, such as vascular endothelial
growth factor (VEGF) and placental growth factor (PGF). This
consequently leads to hypertension in pregnant mice, which is
reversible by CO administration (Linzke et al., 2014).
In addition, because HO-1 can affect oocytes, ovulation, and
the corpus luteum, its deficiency may adversely impact fertility.
For example, HO-1-deficient mice produce fewer oocytes after
hormonal stimulation despite having a normal numbers of folli-
cles, a lower fertilization rate, a lower number of corpus lutea, and
a higher rate of apoptosis in corpus lutea compared to wild-type
(Wt) mice (Zenclussen et al., 2012).
These data do suggest a role for theHO/CO system inmaintain-
ing a healthy pregnancy, starting from the oocyte through the cor-
pus luteum, fertilization, implantation, placentation, and beyond.
In addition, changes in hormonal balance during pregnancy can
in turn affect the HO/CO system and impact normal and patho-
logical pregnancies (Acevedo and Ahmed, 1998; Zenclussen et al.,
2014). Therefore, a detailed study of genotypes along with charac-
terization of the immune cell populations in the various pregnancy
disorders may provide insights into their pathophysiology and
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could lead to the development of novel diagnostic technologies
and therapies involving modulation of the HO/CO axis.
Impact of HO-1 Deficiency on Placentation
The placenta is a complex organ with metabolic, hormonal, and
immune functions. The integrity of its vasculature is critical in
maintaining these functions at the feto-placental interface. In
murine pregnancies, day E10.5 corresponds to the end of the first
trimester in the human pregnancy, and is an important gesta-
tional age (GA) when spiral artery remodeling occurs and the
labyrinth (where feto-maternal exchange occurs) starts to develop.
In pregnant HO-1 heterozygous (HO-1 Het) mice, placental HO-
1 expression and total HO activity change as a function of GA.
After E14.5, HO-1 is primarily found in the spongiotrophoblasts
in the junction zone of the mouse placenta (Wong et al., 2012). At
E16.5, there are significant vasculature differences in the labyrinth
between Wt and HO-1 Het placentas due to differences in pla-
cental angiogenesis (Zhao et al., 2011). Although, basal placental
HO activity is greatest at E15.5 for both pregnant Wt and HO-1
Het mice, HO-1 protein decreases in placentas at E15.5 in HO-1
Het dams, along with a concomitant increase in HO-2 compared
to Wt placentas (Zhao et al., 2009). Total microvasculature vessel
volumes in the labyrinth are largely decreased in the HO-1 Het
placentas and independent of fetal genotype compared toWtmice
(Zhao et al., 2011). These vascular structural alterations in HO-
1 deficient feto-placental units could render the mother and the
fetus more susceptible to environmental stressors, weakening the
feto-placental barrier and, thus, increasing immune trafficking
and disturbing the allograft/host immune homeostasis.
Effect of HO-1 on Immune Cells and Sustaining
the Immunotolerance between the Allograft and
Host
Heme oxygenase-1 is vital for the allograft/host immune home-
ostasis. The majority of knowledge on this topic arises from organ
transplant studies. For example, tolerogenic DCs, which express
high levels of IL-10 and low levels of pro-inflammatory cytokines,
such as IL-12p70, have been shown to prolong allograft survival in
an HO-1-dependent manner in a heart transplant model (Moreau
et al., 2009). In addition, upregulation of granulocytic (CD11b+
Gr1+) MDSCs after a chronic exposure of mice to lipopolysac-
charide (LPS) inhibits T-cell responses in an HO-1-dependent
manner, which delays skin allograft rejection; whereas, inhibiting
HO-1 with tin mesoporphyrin (SnMP) restores allogeneic-driven
T-cell proliferation (De Wilde et al., 2009). Because the fetus
can be considered an allograft, HO-1 also positively impacts
pregnancy outcomes by maintaining a tolerogenic DC profile
and increasing Tregs, hence sustaining feto-maternal immuno-
tolerance. For example, inhibiting HO-1 by zinc protoporphyrin
(ZnPP) decreases Tregs at the feto-maternal interface and results
in fetal allograft rejection; whereas, upregulation of HO-1 by
cobalt protoporphyrin (CoPP) maintains tolerogenic DCs and
increases Tregs and prevents fetal allograft rejection (Sollwedel
et al., 2005; Zenclussen et al., 2007; Schumacher et al., 2012).
At the cellular level, HO-1 is constitutively expressed in
tolerogenic DCs; however, its expression decreases during DC
maturation in vitro. In addition, in human and animal immune
FIGURE 1 | Signaling pathways of HO-1. Green arrows represent
increased HO-1 expression or activity. Red blocked lines represent inhibition
or decreased expression. Several noxious stimuli, highlighted in the green
box, are known inducers of HO-1, as well as hemoglobin/heme through the
CD163 receptor and LPS through the TLR4 receptor. Anti-inflammatory
cytokines are represented in blue; pro-inflammatory cytokines are depicted in
red. There are many cytokine signaling loops that involve HO-1 activity or
expression, including a positive feedback loop between HO-1 and IL-10
(anti-inflammatory), and a negative feedback loop between HO-1 and TNF-a
(pro-inflammatory). HO-1 can inhibit cytokine and chemokine responses such
as IL-1b, IL-8, IL-33, MCP-1, and MIP-1b. The pro-inflammatory chemokine
IL-6 (upregulates HO-1), which in turn inhibits IL-6 to limit inflammatory
responses. Several transcription factors can also bind to the HO-1 promoter
(HMOX1), notably NRF2 at the ARE site, but also AP-1, CREB, and NF-kB
can bind to the promoter at independent binding sites and induce HO-1
expression. Modified and adapted from Ambegaokar and Kolson (2014) with
permission from Bentham Science.
cells (e.g., DCs, monocytes, and macrophages) HO-1 can also
inhibit LPS-induced phenotypic maturation and inflammatory
cytokine secretion and promote anti-inflammatory cytokine pro-
duction (Figure 1). HO-1 is also constitutively expressed by
CD4+CD25+ Tregs in human peripheral blood, and is inducible
in CD4+CD25  naïve T cells upon activation (Biburger et al.,
2010). However, there is general acceptance that the suppressive
functions of Tregs are dependent upon theHO-1 expression status
of the DCs (George et al., 2008) rather than that of Tregs (Zelenay
et al., 2007; Biburger et al., 2010). Interestingly, overexpression
of HO-1 produces an anti-proliferative effect on immune cells,
resulting in an increased number of cells remaining in the G0/G1
phase (Woo et al., 1998) suggesting a cell intrinsic regulatory
mechanism.
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Hence, the HO/CO system may provide some protection
against pathological pregnancies by promoting the development
of a maternal tolerogenic phenotype. In addition, we believe that
such a protective role of HO-1may also be at work in the fetus and
neonate, enabling them to develop an immunotolerant phenotype,
and hence a healthy allograft/host relationship. Because upregula-
tion of theHO/CO system is associatedwith the inhibition of LPS-
induced changes in immune cells, it is possible that such protective
effects might also limit the effects of “pathological inflammation.”
Impact of HO-1 Deficiency on the
Immunomodulatory Functions of Angiogenic
Factors
During normal placental development, HO-1 regulates angio-
genic factors specifically at the decidua andmesometrial lymphoid
aggregate of pregnancy (MLAp) regions of the placenta. HO-1
deficiency, on the other hand, alters the expressions of placenta
angiogenic factors and results in development of a thinner and
structurally-altered placenta inmice. Two of these angiogenic fac-
tors, hypoxia-induced factor-1a (Hif-1a) and hepatocyte growth
factor (Hgf) have immunomodulatory functions (McGettrick and
O’Neill, 2013; Imanirad et al., 2014; Molnarfi et al., 2014) and
are decreased in HO-1-deficient placentas at E10.5 (Zhao et al.,
2011). Normally, Hif-1a, which is abundant in inflammatory M1
macrophages but not in M2 macrophages (Takeda et al., 2010),
attenuates Treg development and activates IL-17-producing Teff
(Th17) cells, which promotes neutrophilic inflammation. Hgf
stimulates tolerogenic DCs and Tregs, decreases Th17 cells, and
downregulates markers of T-cell activation, thereby conferring
immunotolerance (Benkhoucha et al., 2010; Molnarfi et al., 2013).
Hif-1a and Hgf contribute to this important immunoregulatory
balance not only in the placenta; but also, in the central nervous
system (CNS; Benkhoucha et al., 2010; Dang et al., 2011). There-
fore, a decreased expression of Hif-1a and Hgf, in the context of
HO-1 deficiency, may disturb immune homeostasis at the feto-
placental junction, and thus perturb fetal allograft tolerance, espe-
cially when challenged by environmental stressors, particularly
those that result in increased immune cell trafficking and patho-
logical inflammation. Moreover, because these two immunoregu-
latory angiogenic factors are also expressed in the CNS andHif1-a
specifically has a key role in angiogenesis in the CNS andmyelina-
tion (Yuen et al., 2014), we hypothesize that in the HO-1-deficient
fetus, these factors can adversely affect neurodevelopment and
result in periventricular leukomalacia (PVL; Figure 2).
Types of Pathological Pregnancies and the
Protective Role of the HO/CO Pathway
In vivo, the HO/CO system and immunomodulation are closely
linked through a multitude of complex pathways (Tullius et al.,
2002; Soares et al., 2009). Its immunomodulatory role has
been described in many conditions such as organ transplanta-
tion, rheumatologic diseases, multiple sclerosis, and ischemia-
reperfusion injury, pulmonary fibrosis, pulmonary hypertension,
diabetes, in vitro LPS-stimulated immune cells, and in the preven-
tion of pathological pregnancies (Remy et al., 2009; Zenclussen
et al., 2011; Amano and Camara, 2013). The bioactive byprod-
ucts of HO (CO and bilirubin) mediate their anti-inflammatory
and cytoprotective actions principally by downregulating pro-
inflammatory and upregulating anti-inflammatory responses
(Koliaraki and Kollias, 2011). CO regulates various protein
kinases, [e.g., p38mitogen-activated protein kinase (p38MAPK)],
phosphodiesterases, and ion channels, which causes vascular
relaxation, and prevents apoptosis. CO has immunomodulatory
effects on endothelial cells and neutrophils, promotes tolero-
genic DCs and macrophages, and induces expansion of Tregs.
In addition, CO inhibits generation of reactive oxygen species
(ROS) in macrophages, and inhibits activation of Teffs, down-
regulates TLR4 expression, and inhibits the production of pro-
inflammatory cytokines, such as IL-6 and IL-17. Collectively,
these effects of CO promote immunotolerance and protect tissues
from injury (Brouard et al., 2000; Soares et al., 2009; Burt et al.,
2010; Amano and Camara, 2013; Wegiel et al., 2013). In addition,
bilirubin is a free radical scavenger, which also inhibits human
lymphocyte responses, and biliverdin can inhibit complement in
vitro (Nakagami et al., 1993; Haga et al., 1996).
Hence, these effects of the HO/CO pathway may be impor-
tant in maintaining a healthy allograft/host relationship, and CO
may have a role as an immunomodulator in the prevention or
treatment of pregnancy complications. Because CO is a gas, its
beneficial effects could also be extended to the fetus and neonate.
Infertility, Abortions, and Miscarriages
In women with infertility, failed in vitro fertilization (IVF)
attempts, or recurrent spontaneous miscarriages, a decrease in
Tregs, an increase Th17 cells, an imbalance of Th1/Th2 cells
and their cytokines, as well as abnormalities in MDSC and NK-
cell populations and function have been reported in peripheral
blood and decidua (Saito et al., 2010; Dimova et al., 2011; Lash
and Bulmer, 2011; Schlossberger et al., 2013; Kim et al., 2014;
Kamoi et al., 2015; Zhao et al., 2015). Such immune imbalances,
however, have not been observed in electively-induced abortions
in humans (Caliendo, 2007; Zenclussen et al., 2007). Therefore,
infertility and spontaneous miscarriages could be a function of
such disturbed immune homeostasis, and careful modulation of
the HO/CO pathway might help restore homeostasis and improve
pregnancy outcomes.
The use of metalloporphyrins, synthetic analogs of heme, to
modulate the HO/CO pathway has provided some insight into its
relevance in pregnancy in murine abortion-models. For example,
the administration of CoPP increases HO-1 and HO-2 expression
significantly in spongiotrophoblasts, labyrinth, and giant cells,
and prevents abortions by upregulating the cytoprotective, anti-
apoptotic molecule Bag-1 and neuropilin-1, a marker for Tregs,
in the placenta. In contrast, inhibiting HO with ZnPP increases
abortions. This protection of HO from abortions is attributed to
the immunoregulatory role of Tregs (Sollwedel et al., 2005).More-
over, CO administration, in addition to preventing abortions,
improves litter weights in animal models (Zenclussen et al., 2011;
El-Mousleh et al., 2012), suggesting a protective effect of HO-1
upregulation and increased CO production in the neonate.
Infection and inflammation probably disrupts this delicate
immune balance, which may be accentuated in HO-1 deficiency.
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FIGURE 2 | Model of inflammatory/infection-mediated
neuropathogenesis in HO-1 deficiency. Infection/inflammation-activated
immune cells, including CD4+ T cells and CD14+ monocytes, circulate through
the blood and produce reactive oxygen species (ROS). Infected or activated
immune cells can also release the pro-inflammatory cytokines, TNF-a and IL-1b,
which ROS can exacerbate. ROS contribute to increased blood–brain barrier
(BBB) permeability, which can allow for increased entry of activated immune cells
(e.g., monocytes) from the blood into the newborn brain. Effector T-cells (Teffs)
lymphocytes may also enter the brain. As monocytes enter the brain, they
differentiate into macrophages, and release IFN-g in addition to TNF-a and
activate microglia. Both macrophages and microglia can produce IFN-g and
TNF-a in a positive feedback loop, and can release a host of neurotoxic and
oligodendroglial toxic factors. Most neurotoxicity is initially limited to synaptic loss
and decrease in dendritic density that is dependent on the NMDA-type glutamate
receptor. This leads to eventual loss of neuronal function and finally neuronal
death. We hypothesize that in HO-1 deficiency, an increase in TNF-a, IL-1b,
IFN-g, ROS, glutamate, and free iron (Fe++) results in the arrest of
oligodendrocyte maturation, axon-oligodendrocyte synaptic damage, a decrease
in oligodendrocyte numbers, a decrease in myelination and results in
periventricular leukomalacia (PVL). Activated astrocytes have abnormal glutamate
metabolism, leading to excess glutamate release and excitotoxicity. TNF-a and
IL-1b stimulation of astrocytes can further increase glutamate release.
Astrocytes, microglia and macrophages are potent inducers of HO-1, which is
downregulated in infected macrophages and in infected brains, and thus may
also contribute to neuropathogenesis of infection; neurons demonstrate very
limited expression of HO-1. Red arrows indicate potential neurotoxins or direct
neurotoxic/oligodendroglial toxic pathways. Modified and adapted from
Ambegaokar and Kolson (2014) with permission from Bentham Science.
For example, Kahlo et al. (2013) have shown that after an in
vitro LPS challenge, normal human trophoblasts harvested in
the first trimester are able to upregulate HO-1; however, HO-
1 upregulation is diminished in trophoblasts from spontaneous
abortions, which is associated with a decreased expression of Bag-
1 and fetal allograft rejection. Thus, individuals deficient in HO-1
may be at a higher risk for adverse pregnancy outcomes under
stress (e.g., infection and inflammation). Gene-based therapy
using adenoviral transfer of the HO-1 gene has been shown to
prevent abortions in mice, but only if expression is not too high
(Zenclussen et al., 2006). Therefore, interventions to upregulate
theHO/COpathwaymight be considered as ameans of alleviating
early and/or late pregnancy complications, although control of the
appropriate dose will likely be important.
Pre-eclampsia
Pre-eclampsia is diagnosed when there is an onset of hyper-
tension beyond the 20th week of gestation as defined by the
American College of Obstetricians and Gynecologists (ACOG)
criteria (Schroeder and ACOG, 2002). Its pathogenesis is still
being investigated, but is believed related to vascular, endothe-
lial, and immunologic alterations. HO-1 can regulate placental
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angiogenesis through both VEGF and sFlt-1 (soluble VEGFR-
1); sFlt-1 is produced in mouse and human placentas during
later stages of gestation and is an important marker for pre-
eclampsia with increased levels correlating with increasing sever-
ity of pre-eclampsia (Hirashima et al., 2003; Ahmed, 2011; Ander-
son et al., 2012). It has been suggested that the development of
pre-eclampsia in HO-1 deficiency might be facilitated by increas-
ing sFlt-1 secretion (Ahmed, 2011). In contrast, upregulation of
HO-1 and its byproduct CO can inhibit sFlt-1 secretion, thereby,
alleviating pre-eclampsia (Ahmed, 2011). Because LPS can trigger
the release of sFlt-1 from monocytes (Redecha et al., 2009), peri-
natal infections might further complicate or worsen pregnancy
outcomes, particularly in women who are prone to pre-eclampsia.
Immunologic alterations, such as generalized inflammation
and activation of certain immune pathways, are thought to play
important roles in the pathogenesis of pre-eclampsia. At a cel-
lular level, pre-eclampsia is associated with a predominance of
M1 inflammatory macrophages at the feto-placental interface,
activation of granulocytes and monocytes, a decrease in iTregs,
and abnormalities in uNK cells and Th17 cells (Cerdeira et al.,
2012; Faas et al., 2014; Fu et al., 2014; Wallace et al., 2015).
To date, the immunomodulatory effects of the HO/CO system
on macrophages in pre-eclamptic placentas have not been well
defined. In a spontaneously hypertensive rat model, induction of
HO-1 by heme enhances immunomodulatory M2 macrophages
and suppresses inflammatory M1macrophages and their produc-
tion of the pro-inflammatory chemokines MCP-1 and MIP1-a,
which stimulate macrophage infiltration (Ndisang and Mishra,
2013). In contrast, M2 macrophages are believed to be beneficial
and promote immunotolerance in pregnancy, but they have also
been shown to release high levels of iron after tissue injury and
hemorrhage (Sica and Mantovani, 2012). Therefore, we specu-
late that in some pregnancy complications, especially in HO-1-
deficient humans, a predominance of M2 macrophage may lead
to a greater tissue iron load and result in a “reversed” phenotype,
where tissue injury may still occur due to an iron-associated
oxidative injury.
Administration of exogenous CO to pregnant HO-1-deficient
mice has been shown to directly induce uNK cell proliferation
possibly through the modulation of interferon-gamma (IFN-g)
and prevent the development of a pre-eclampsia-like syndrome
and IUGR, independent of sFlt-1 and sEng (Linzke et al., 2014). It
has been shown that offspring born to pre-eclamptic mothers are
at an increased risk developing metabolic syndrome later in life
due to prenatal programming (Barker hypothesis) via epigenetic
effects (Tenhola et al., 2003; Vatten et al., 2003). In a sponta-
neous hypertensive rat model, the induction of HO-1 decreases
total cholesterol and triglyceride levels and improves glucose
metabolism by potentiating insulin signaling, thereby decreasing
the likelihood of developing metabolic syndrome (Ndisang and
Mishra, 2013).
Preterm Labor
The etiologies of preterm labor are still under debate, but devel-
opment of a “pathologic” inflammation by the mother is probably
an important contributing factor (Capece et al., 2014). The major
role of immune system alterations in preterm labor can be best
demonstrated by comparing it to normal parturition at term
(Nagamatsu and Schust, 2010a). Vince et al. (1990) reported that
in early and term human deciduas, almost half of the cells are
leukocytes (CD45) and of the hematopoietic lineage, emphasizing
the importance of the immune system in pregnancy. In normal
parturition, a “physiologic” inflammation is initiated by mono-
cytes and macrophages that infiltrate the term placenta, maternal
decidua, and the fetal membranes and contribute to spontaneous
membrane rupture and normal labor; whereas, the infiltration of
monocytes and neutrophils confer post-partum decidual involu-
tion (Halgunset et al., 1994; Thomson et al., 1999; Shynlova et al.,
2013a,b).
In preterm labor, this well-orchestrated immune sequence is
lost. For example, neutrophils become the predominant decidual
and myometrial leukocytes (Shynlova et al., 2013a). In human
preterm deliveries, the tolerogenic immune phenotype switches
to an inflammatory phenotype. Here, the suppressive capacity of
Tregs decreases despite total Tregs remaining the same and selec-
tive immunotolerance for the fetus is lost, which subsequently
results in preterm delivery or “allograft” rejection (Schober et al.,
2012). In addition, a pathological activation of complement, neu-
trophils, monocytes, and Teffs have been observed in both human
and mice preterm labor further supporting the theory of immune
imbalance and allograft rejection (Gervasi et al., 2001; Diamond
et al., 2007; Saito et al., 2010; Shynlova et al., 2013a; Gonzalez
et al., 2014). Moreover, it has been shown that the preterm labor
inducing effects of pathological complement activation can be
eliminated by HO-1 induction (Gonzalez et al., 2014).
Preterm Premature Rupture of Membranes, Fetal
Inflammatory Response Syndrome, Funisitis,
Chorioamnionitis, and Neurodevelopmental
Outcomes
Preterm premature rupture of membrane (PPROM) is associated
with inflammation in most cases and may be linked to colla-
gen, matrix, hematologic, and coagulation abnormalities (Capece
et al., 2014). In some instances of PPROM, a continuum of infec-
tion, fetal inflammatory response syndrome (FIRS), funisitis, and
chorioamnionitis ensues and can lead to adverse neurodevelop-
mental outcomes (Burd et al., 2012). In a co-stimulation assay
using peripheral blood mononuclear cells (PBMCs) from mater-
nal/fetus pairs, Steinborn et al. (2005), have shown that maternal
PBMCs, after stimulation with PBMCs derived from their respec-
tive fetuses, have an increased stimulation index if mothers had
PPROM. This suggests that a disruption of feto-maternal toler-
ance occurs; whereas, in maternal/fetus pairs without PPROM,
PBMC co-stimulation assays show decreased stimulation indices
(Steinborn et al., 2005). The continuum of infection, FIRS, funisi-
tis, and chorioamnionitis requires the activation of umbilical cord
endothelial cells and the infiltration of maternal inflammatory
cells across the placental layers toward the fetus. For example,
FIRS is associated with maternal peripheral blood leukocytosis
(Bartkeviciene et al., 2013), and a predominance of activated
neutrophils and monocytes in the cord blood of newborns with
funisitis (Kim et al., 2009). In contrast, in LPS-stimulated term
umbilical cord blood neutrophils, bilirubin, a product of the HO
reaction, induces antioxidants superoxide dismutase (SOD) and
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HO-1 expression and decreases the production of the inflam-
matory cytokine IL-8 and the chemokine MIP-1b in a dose-
dependent manner, conferring protection from LPS (Weinberger
et al., 2013). A role for HO-1 deficiency in the context of infection
and protection by endogenous HO-1 induction is well defined
in some neurodegenerative diseases (Ambegaokar and Kolson,
2014). In LPS-treated mice, HO-1 induction by statins inhibits
complement and decreases apoptosis in fetal cortical neurons,
thereby conferring protection from fetal cortical neuronal injury
(Pedroni et al., 2014).
HO-1 and Perinatal Infections
A number of human and mouse studies have shown the con-
tribution of pregnancy-associated infections and inflammation
to adverse pregnancy outcomes (septic abortions, PPROM,
FIRS, preterm delivery, and chorioamnionitis) and fetal/
neonatal outcomes (early onset sepsis, autism, learning dis-
abilities, schizophrenia, abnormalities of neuronal migration,
and PVL). Maternal bacterial infections during mid-to-late
pregnancies are probably the most clinically relevant for causing
such adverse neonatal outcomes. Among very low birth weight
(VLBW) infants, gram-negative bacterial infections, especially
E. coli, can cause increased morbidity and mortality. Dorresteijn
et al. (2015) have recently shown that LPS stimulation selectively
downregulates HO-1 expression in PBMCs, monocytes,
granulocytes, macrophages, and DCs from healthy male
donors via stimulating Bach1, which transcriptionally represses
HO-1 expression. However, similar LPS stimulation results in
upregulation of HO-1 expression inmouse lungmacrophages and
human monocytic leukemia cell lines (Dorresteijn et al., 2015).
Therefore, further research is necessary to better characterize
HO-1 responses in immune cells during a healthy normal
pregnancy, as well as during gram-negative infections during
pregnancy and in the neonate and associated complications.
Vertical transmission of maternal viral infections [e.g., herpes
simplex virus (HSV), human immunodeficiency virus (HIV), and
cytomegalovirus (CMV)] can adversely affect pregnancy, fetal,
and neonatal outcomes. For example, HSV and HIV can cause
encephalitis and/or neurodegeneration. A relative deficiency in
HO-1 has been suggested to play a role for viral encephalitis
(HSV, HIV) in non-pregnant individuals (Schachtele et al., 2012;
Gill et al., 2014). On the other hand, HO-1 has been reported
to have a protective role in HIV-induced neurocognitive dis-
orders (Ambegaokar and Kolson, 2014). Thus, further studies
are required on whether HO-1 deficiency adversely affects the
offspring’s neurodevelopment during a maternal HSV or HIV
infection. In addition, it has been recently shown that in an in
vitro CMV model using human PBMCs, HO inhibition by SnMP
resulted in an expansion of CD8 cytotoxic T-cells, which may be
helpful in controlling this viral infection (Bunse et al., 2014); these
effects were also found to be cell-type specific, as uNK cells and
DCs were not affected.
Heme oxygenase-1 is found to be protective in septic abortions
due to gram-positive (Listeria monocytogenes; Tachibana et al.,
2011) and -negative (Brucella abortus; Tachibana et al., 2008)
infections in murine models. A common mechanism is that
both gram-positive and -negative bacteria may decrease HO-1
expression in trophoblastic giant cells and increase apoptosis
leading to abortions, which can be prevented by the induction of
HO-1. Trichomonas is an extracellular parasitic organism that is
associated with preterm delivery in humans. In amurinemodel of
trichomoniasis, this infection resulted in an increased incidence
of septic abortions that were associated with a decreased in
HO-1 expression in uterine tissues and a concomitant increase in
Th17 responses as reflected by an increase in RORgt expression,
a transcription factor that promotes Th17 differentiation
(Woudwyk et al., 2012).
Possible Pharmacological Therapies
Affecting HO-1 Expression and/or Immune
System in Pregnancy
Statins
These compounds are 3-hydroxy-3-methyl-glutaryl–coenzyme A
(HMG-CoA) reductase inhibitors, which are known for their use
in reducing cholesterol levels. They have been shown to have anti-
oxidant, anti-inflammatory, and immunomodulatory properties
(Muchova et al., 2007). We have shown that statins can induce
HO-1 expression in a tissue-specific and also in a statin-specific
manner (Hsu et al., 2006). For example, atorvastatin increases
HO-1 expression in the heart, and both rosuvastatin and ator-
vastatin increase HO activity, increase tissue CO content and
bilirubin in the heart, and increase plasma bilirubin, effects that
collectively confer protection from oxidative stress (Hsu et al.,
2006; Muchova et al., 2007). Simvastatin can induce HO-1 in
human umbilical vein endothelial cells in vitro (Hinkelmann et al.,
2010). Pravastatin has been shown to have the most promise for
use in the prevention of pre-eclampsia since it does not cross
the placenta and exerts its anti-inflammatory and immunomod-
ulatory effects by suppressing sFlt and sEng. A recent study by
McDonnold et al. (2014) demonstrated that the adverse conse-
quences of pre-eclampsia in offspring, such as the late manifesting
metabolic syndrome, can be alleviated by pravastatin. Statins have
been shown to modulate the immune system by upregulating
HO-1 mRNA expression in murine macrophage cultures (Chen
et al., 2006). In pre-eclampsia, increased inflammation does not
precede, but rather follows its onset since vascular imbalances
seem to be important in the pathogenesis (Ramma and Ahmed,
2011; Faas et al., 2014). This suggests that the anti-inflammatory
effects of theHO/COpathwaymight be important in ameliorating
pre-eclampsia after it is diagnosed clinically. However, statins are
not FDA-approved for use in pregnancy. Because pravastatin is
hydrophilic and does not cross the feto-placental barrier, it was
chosen as the drug of choice for the “Statins to Ameliorate Early
Onset Pre-eclampsia Trial” (Ramma and Ahmed, 2014). Further-
more, theNational Institutes of Health (NIH) started a pravastatin
pharmacokinetics trial in pregnant women at high-risk for pre-
eclampsia (Costantine et al., 2013). However, the results of these
two clinical trials are not currently available.
Aspirin
Acetyl-salicylic acid (aspirin), an irreversible cyclo-oxygenase
inhibitor, is anti-pyretic, analgesic, and anti-inflammatory.
Low-dose aspirin has been proven effective for highly morbid
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Low-dose aspirin is also utilized for the pre-conceptional treat-
ment of infertility, and for the post-conceptional prevention of
recurrent miscarriages in some women (Lambers et al., 2009;
Dentali et al., 2012; de Jong et al., 2014). However, its utility in
the prevention of pregnancy complications has been under debate.
In a recent multicenter, double blind, randomized control clinical
trial [“Effects of Aspirin in Gestation and Reproduction (EAGer)”],
pre-conception low-dose aspirin use as a primary prevention
strategy did not increase live birth rates nor preventmiscarriages if
the women had a prior history of miscarriages (Schisterman et al.,
2014). Low-dose aspirin, also has not been effective in prevention
of pre-eclampsia (Cantu et al., 2015). It has been shown that
aspirin pre-treatment, increasesHO-1 activity and protein expres-
sion in vitro in human umbilical cord endothelial cell cultures and
decreases oxidative injury and increases survival of endothelial
cells (Grosser et al., 2003). However, therapeutic doses of aspirin
failed to induce HO activity and HO-1 protein levels in vivowhen
given to healthy human subjects in conjunction with simvastatin
or a-lipoic acid (Bharucha et al., 2014). Further studies are needed
in pregnancy.
Immunomodulatory Therapies
Most animal studies have shown that an activation of the innate
immune system and subsequent release of detrimental cytokines
in the placenta and fetus occur within several hours of encounter-
ing an inflammatory stimulus. Most studies using animal models
have been designed as “pre-treatment” strategies of pregnant dams
using a tumor necrosis factor (TNF)-a-suppressing drug, such as
pentoxifylline (Gendron et al., 1990), or a TNF-a receptor agonist,
such as etanercept (Carpentier et al., 2011). Despite being proven
effective as preventative measures in rodent pregnancies, these
compounds cannot be recommended for use in humans during
pregnancy, although there is evidence that pentoxifylline may
increase pregnancy rates in sub-fertile women as reported in a
recent Cochrane review (Showell et al., 2013).
Cell-Based Immunotherapies
In a recent study using intradermal desensitization with paternal
or third party peripheral lymphocytes for recurrent spontaneous
abortion patients, Tregs increased in peripheral blood while Th17
cells decreased. A favorable cytokine profile was achieved in a
majority of these women, who then proceeded to have a healthy
pregnancy after immunotherapy (Wu et al., 2014). Whether these
cell-based immunotherapies could be used for infection-related
pregnancy complications remains to be proven. Although data
are lacking for pregnant women, studies in immunosuppressed
post-transplantation patients have shown that adoptive transfer
of viral-specific cytotoxic CD8 T lymphocytes can help control
CMV infections. Targeting CMV and other viral, bacterial, and
fungal infections during pregnancy may be possible utilizing
cell-based immunotherapies. Mesenchymal stromal cells (MSCs)
have immunosuppressive properties partly attributed to the HO-
1 pathway and are used in graft vs host disease (GVHD) as a
therapeutic strategy by some investigators (Stagg and Galipeau,
2013). In contrast, the involvement of HO-1 in MSCs immuno-
suppression has been recently disputed by a study by Patel et al.
(2015) utilizing MSCs from healthy donor bone marrows and
stimulating them with inflammatory mediators in an in vitro
model. The use of MSCs in pregnancy cannot be advocated at this
time.
Conclusion
Infertility, miscarriages, abortions, pre-eclampsia, preterm labor,
PPROM, infection/inflammation during pregnancy,maternal and
fetal deaths, prematurity, small-for-gestational-age newborns, and
resulting adverse neonatal neurodevelopmental outcomes are
some of many the consequences of pathologic pregnancies. The
causal pathways shared by these adverse outcomes may relate to
the disrupted allograft/host immune homeostasis, which can be
altered further in the context of a relative deficiency in HO-1.
As with most protective mechanisms in the body, the HO/CO
pathway can be influenced by host factors, such as HO-1 poly-
morphisms or challenged by environmental stressors, such as
infection or inflammation. These environmental stressors result
in “pathological” inflammation, perhaps more so in mother/fetus
pairs unable to upregulate the HO-1 sufficiently to meet the
demands.
Heme oxygenase-1 appears to have diverse protective roles
in pregnancy, including in sustaining a healthy oocyte and
subsequent fertilization, optimizing placental vascular develop-
ment and spiral artery remodeling, facilitating a tolerogenic allo-
graft/host environment, and extending these immunoprotective
effects to the fetus, and subsequently to the neonate. The use of
compounds or treatment strategies to upregulate this pathway in
an immune cell-specificmanner could be a promising approach to
preventing, alleviating, and/or treating pregnancy complications,
as well as adverse neonatal outcomes in the future.
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